Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

In a phase Ib trial, anti-CD47 mAb AK117 in combination with Aza demonstrated favorable tolerance and a 54.2% CR rate in newly diagnosed high-risk MDS patients (71). Table 7 Targeting CD47 related ...

Income as a percentage of RWAs in the IB rose to 7.7% in the first quarter ... both by taking in dozens of CS bankers and by recruiting MDs from rivals. They include a team from Barclays led ...

NEET MDS Admit Card 2025 Out: The National Board of Examinations in Medical Sciences (NBEMS) has officially released the NEET MDS 2025 admit card on 15th April 2025. Candidates appearing for the ...

NEET MDS 2025: The National Board of Examinations in Medical Sciences (NBEMS) will close the NEET MDS 2025 application window today, April 6. Candidates can apply for the examination at natboard ...

For our R289 program in lower-risk MDS, we expect to complete the dose escalation portion of the Phase Ib study. The new six dose level, 500 milligrams twice daily is actively enrolling.

The decision to reopen the registration window was taken after the last date of completion of internship towards eligibility for NEET-MDS 2025 was extended till June 30, 2025. Candidates can ...

Patient-reported outcomes, including activities of daily living and quality of life, were evaluated using the Spanish version of the MDS-UPDRS Part IB (non-motor experiences of daily living) and Part ...

In this phase Ib, multi-center, multi-site ... motor symptoms as reported via the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and PD Motor Diary self-assessments, ...

STTK's Phase IB SL-172154 Study Shows Limited Efficacy Shattuck ... to treat patients with TP53 mutant (TP53m) AML and HR-MDS. Per the interim analysis results, treatment with the combo therapy ...

The IND supports the initiation of a Phase Ib dose exploration clinical trial of MNV-201 in patients with Low Risk Myelodysplastic Syndrome (MDS). Anemia is a common and serious symptom in patients ...

The IND supports the initiation of a Phase Ib dose exploration clinical trial of MNV-201 in patients with Low Risk Myelodysplastic Syndrome (MDS). Anemia is a common and serious symptom in ...